Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Price Down 5.7% – Here’s What Happened

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s share price dropped 5.7% during mid-day trading on Thursday . The stock traded as low as $11.85 and last traded at $11.85. Approximately 170 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 14,562 shares. The stock had previously closed at $12.57.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Santen Pharmaceutical presently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Down 1.1%

The firm has a market cap of $3.82 billion and a price-to-earnings ratio of 0.10. The stock has a fifty day moving average price of $11.19 and a 200 day moving average price of $10.84.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.